



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## Neovacs® raises €2.25 million in new capital at €4 per share

- **Debioinnovation SA, part of the Swiss Debiopharm group, invests €1 million in Neovacs® shares**
- **Two other existing institutional shareholders, Truffle Capital and OTC Asset Management, increase their stake in Neovacs®' capital**

**Paris, 1<sup>st</sup> April 2011** - Neovacs® (Alternext Paris: ALNEV), a biotech company focused on an active immunotherapy technology platform (Kinoids™) with applications in the treatment of autoimmune diseases, inflammatory diseases and cancer, today announced that new equity capital has been subscribed for a total of €2.25 million. As a consequence 562,500 new shares have been issued at a price of €4 per share.

Debioinnovation SA, part of the Swiss Debiopharm Group, has invested €1 million. As of today and following this investment, Debioinnovation SA has no further outstanding investment rights or obligations relating to Neovacs®.

In addition, two of Neovacs®' historical institutional investors, Truffle Capital, the largest shareholder and the first institutional investor of Neovacs®, with OTC Asset Management, have decided to subscribe for a total of €1.25 million, by issuance of 262,500 new shares at the same price of 4 euros per share.

For this capital increase, Neovacs® has issued 562,500 new shares which have been subscribed, raising the number of shares outstanding from 12,991,673 to 13,554,173.

*“By investing in our company, Debioinnovation SA, Truffle Capital and OTC Asset Management demonstrate their confidence in the potential of our two drug candidates, the TNF-Kinoid and the IFN $\alpha$ -Kinoid. These additional funds further strengthen our cash position and contribute to the financing of the three clinical trials on going”,* stated Guy-Charles Fanneau de La Horie, Neovacs® CEO.

At 31<sup>st</sup> December 2010, net cash available was €8.4 million.

### **About Neovacs®**

Neovacs® is a biotechnology company focused on an active immunotherapy technology platform (Kinoids™) with applications in autoimmune diseases and other chronic conditions. Neovacs® proprietary technology, protected by five patent families, aims to induce a polyclonal immune response from the patient's own immune system targeting an over-expressed cytokine. Neovacs®' current portfolio consists of 3 drug candidates: TNF-Kinoid, IFN $\alpha$ -Kinoid and VEGF-Kinoid. The company's lead immunotherapy program (TNF-Kinoid) targets TNF-mediated chronic inflammatory diseases. For TNF-Kinoid, a Phase I/II clinical trial in Crohn's disease has been completed and Phase II trials in rheumatoid arthritis (RA) and Crohn's Disease are ongoing. The RA clinical study is also the focus of collaboration with the French diagnostics company BMD, with the goal of developing theranostic tools for personalized care in RA. Patient recruitment is complete in a Phase I/II trial of Neovacs®' second product candidate (IFN $\alpha$  - Kinoid, an immunotherapy targeting interferon alpha) in the treatment of lupus.

**For more information, visit the Neovacs® website at [www.neovacs.com](http://www.neovacs.com)**

### **Contacts:**

#### **Press - MS&L**

Audrey Saluzzo  
+33 (0)1 58 47 78 56  
[audrey.saluzzo@mslgroup.com](mailto:audrey.saluzzo@mslgroup.com)

#### **Neovacs**

Florence Hocdée - Leroy  
+33 (0) 1 53 10 93 14  
[fhocdeeleroy@neovacs.com](mailto:fhocdeeleroy@neovacs.com)

#### **Investors – Actifin**

Nicolas Meunier  
+ 33 (0) 1 56 88 11 11  
[nmeunier@actifin.fr](mailto:nmeunier@actifin.fr)